

A DECADE OF INNOVATION

Over the past decade, innovative products have changed the landscape of the pharmaceutical industry. In this infographic, we highlight some of the biggest shifts, with increased investment and development of biologics, recombinant DNA, and gene research. We also explore the impact on resources; bringing biologics to market is more expensive, takes longer, and serves a smaller population of patients, lowering the opportunity for revenue. Looking forward, we showcase future innovation opportunities within the industry.



GROWING COST: BRINGING A PRODUCT TO MARKET



Innovative products, such as biologics, require more time and money to develop, test, and reach the market. An influx of such products has caused the cost of bringing an asset to market to rise over the last decade by

67%

Source: Deloitte, 2020

THE FUTURE OF BIOPHARMA INNOVATION



Shift to small molecule research – accommodate emerging modalities to remain competitive



Expedite pace of scientific breakthroughs – insight from interoperable data



Move away from tradition – dataset-driven processes, intelligent computing, and cloud storage



Advance analytics – end-to-end automation of R&D

Source: Deloitte, 2020

SOURCES OF INNOVATION

Mergers, acquisitions, and co-development are all being increasingly relied upon for innovation in large cap biopharma.

In 2019...



of forecast sales were attributed to acquisitions

26%

of forecast sales were attributed to co-development

Source: Deloitte, 2020